购物车
- 全部删除
- 您的购物车当前为空
Opnurasib (JDQ-443) 是一种可口服且具有选择性和有效性的共价 KRAS G12C 抑制剂,具有抗肿瘤活性,可用于研究晚期非小细胞肺癌。
Opnurasib (JDQ-443) 是一种可口服且具有选择性和有效性的共价 KRAS G12C 抑制剂,具有抗肿瘤活性,可用于研究晚期非小细胞肺癌。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 1,250 | 现货 | |
5 mg | ¥ 3,150 | 现货 | |
10 mg | ¥ 4,590 | 现货 | |
25 mg | ¥ 7,280 | 现货 | |
50 mg | 询价 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 3,630 | 现货 |
产品描述 | Opnurasib (JDQ-443) is an orally available and selective and potent covalent KRAS G12C inhibitor with antitumor activity for the study of advanced non-small cell lung cancer. |
体外活性 | Opnurasib selectively forms a covalent bond with and inhibits GDP-bound KRASG12C, demonstrating a low reversible binding affinity to the RAS switch II pocket. Additionally, it effectively hinders the proliferation of cell lines carrying KRASG12C mutations, as well as those with double mutations G12C/H95, G12C/R68S, and G12C/Y96.[2] Opnurasib induces dose-dependent decreases in phosphorylated ERK (pERK) levels and inhibits the proliferation of KRASG12C-mutated cell lines NCI-H358 and NCI-H2122, exhibiting IC50 values of 0.018 and 0.063 μM, respectively.[2] |
体内活性 | Opnurasib elicits distinct antitumor responses in patient-derived xenograft (PDX) models of non-small cell lung cancer (NSCLC) and colorectal tumors, and these responses are further enhanced when Opnurasib is used in combination with other therapeutic agents.[2] |
别名 | Opnurasib, NVP-JDQ443, JDQ-443 |
分子量 | 526.03 |
分子式 | C29H28ClN7O |
CAS No. | 2653994-08-0 |
Smiles | Cc1c(c(nn1C1CC2(C1)CN(C2)C(=O)C=C)-c1ccc2n(C)ncc2c1)-c1c(Cl)c(C)cc2[nH]ncc12 |
密度 | 1.46 g/cm3 (Predicted) |
存储 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 70 mg/mL (133.07 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容